期刊文献+

Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis:A randomized,double blind,placebo-controlled,multicenter clinical study 被引量:18

Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis:A randomized,double blind,placebo-controlled,multicenter clinical study
下载PDF
导出
摘要 AIM: To evaluate the efficacy and safety of oxymatrine capsule in treatment of hepatic fibrosis in patients with chronic viral hepatitis. METHODS: It was a randomized, double blind, placebocontrolled, multicenter clinical study. One hundred and fortyfour patients were divided into oxymatrine capsule group (group A) and placebo group (group B). The course was 52wk. Patients were visited once every 12wk and the last visit was at 12wk after cessation of the treatment. All patients had liver biopsy before treatment, part of them had a second biopsy at the end of therapy. Clinical symptoms, liver function test, serum markers of hepatic fibrosis were tested. Ultrasound evaluation was performed before, during and at the end of therapy. RESULTS: One hundred and forty-four patients enrolled in the study. Of them 132 patients completed the study according to the protocol, 49 patients had liver biopsy twice (25 patients in group A and 24 in group 13). At the end of therapy, significant improvements in hepatic fibrosis and inflammatory activity based on Semi-quantitative scoring system (SSS) were achieved in group A. The total effective rate of the treatment was 48.00%, much higher than that of 4.17% in group B (P<0.05). Significant improvement in serum markers of hepatic fibrosis such as hyaluronic acid (HA) and type Ⅲ procollagenic peptide (PⅢ P) in group A was seen (P<0.05). The total effective rate of serum markers at the end of therapy in group A was 68.19%, much higher than that of 34.85% in group B (P<0.05). The total effective rate of noninvasive markers at the end of therapy in group A was 66.67%, much higher than that of 30.30% in group B (P<0.05). The rate of adverse events was similar in two groups. CONCLUSION: Oxymatrine capsule is effective and safe in treatment of hepatic fibrosis due to chronic viral hepatitis. AIM:To evaluate the efficacy and safety of oxymatrine capsule in treatment of hepatic fibrosis in patients with chronic viral hepatitis. METHODS:It was a randomized,double blind,placebo- controlled,multicenter clinical study.One hundred and forty- four patients were divided into oxymatrine capsule group (group A)and placebo group(group B).The course was 52 wk.Patients were visited once every 12 wk and the last visit was at 12 wk after cessation of the treatment.All patients had liver biopsy before treatment,part of them had a second biopsy at the end of therapy.Clinical symptoms,liver function test,serum markers of hepatic fibrosis were tested.Ultrasound evaluation was performed before,during and at the end of therapy. RESULTS:One hundred and forty-four patients enrolled in the study.Of them 132 patients completed the study according to the protocol,49 patients had liver biopsy twice(25 patients in group A and 24 in group B).At the end of therapy,significant improvements in hepatic fibrosis and inflammatory activity based on Semi-quantitative scoring system(SSS)were achieved in group A.The total effective rate of the treatment was 48.00%,much higher than that of 4.17% in group B (P<0.05).Significant improvement in serum markers of hepatic fibrosis such as hyaluronic acid(HA)and type Ⅲ procollagenic peptide(P Ⅲ P)in group A was seen(P<0.05).The total effective rate of serum markers at the end of therapy in group A was 68.19%,much higher than that of 34.85% in group B(P<0.05).The total effective rate of noninvasive markers at the end of therapy in group A was 66.67%,much higher than that of 30.30% in group B(P<0.05).The rate of adverse events was similar in two groups. CONCLUSION:Oxymatrine capsule is effective and safe in treatment of hepatic fibrosis due to chronic viral hepatitis.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2004年第22期3269-3273,共5页 世界胃肠病学杂志(英文版)
基金 Supported by Grants From the Key Project of Shanghai Medical Development Foundation,NO:99ZDI001 Grants From 1999 Youth Liver Diseases Foundation of Chinese Liver Diseases Association
  • 相关文献

参考文献5

二级参考文献20

  • 1陈福祥,刘晶星,陆德源.苦参总碱体外抗柯萨奇B病毒3型作用测定及其机理的初步研究[J].中华实验和临床病毒学杂志,1995,9(2):115-118. 被引量:64
  • 2陈伟仲,第二军医大学学报,1996年,17卷,5期,424页
  • 3张俊平,第二军医大学学报,1996年,16卷,6期,413页
  • 4丁劲行,中华内科杂志,1990年,29卷,11期,648页
  • 5Chun YK,Kim JY,Woo HJ,Oh SM,Kang IS,Ha JH, et al.No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection. Hepatology . 2000
  • 6Honda A,Yokosuka O,Fhata T, et al.Detection of mutations in the enhancer 2/core promoter region of hepatitis B virus in patients with chronic hepatitis B virus infection: comparison with in precore and core regions in relation to clinical status. Journal of Medical Virology . 1999
  • 7Habersetzer F,Zoulim F,Jusot JF, et al.Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B e antigen and treated with interferon-alpha. Journal of Viral Hepatitis . 1998
  • 8Lindh M,Horal P,Dhillon AP, et al.Hepatitis B virus DNA levels, procure mutations, genotypes and histological activity in chronic hepatitis B. Journal of Viral Hepatitis . 2000
  • 9Grandjacques C,Pradat P,Stuyver L, et al.Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. Journal of Hepatology . 2000
  • 10Tu H,,Xiong SD,Trepo C, et al.Frequency of hepatitis B virus e-minus mutants varies among patients from different areas of China. Journal of Medical Virology . 1997

共引文献142

同被引文献114

引证文献18

二级引证文献136

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部